Nifty
Sensex
:
:
12100.25
41230.59
-13.20 (-0.11%)
-51.10 (-0.12%)

Pharmaceuticals & Drugs

Rating :
55/99  (View)

BSE: 532321 | NSE: CADILAHC

268.85
-1.15 (-0.43%)
17-Feb-2020 | 11:54AM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  271.30
  •  276.80
  •  266.70
  •  270.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1338422
  •  3598.35
  •  352.60
  •  206.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 27,625.69
  • 22.19
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 34,875.79
  • 1.30%
  • 2.59

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.88%
  • 1.11%
  • 5.73%
  • FII
  • DII
  • Others
  • 4.58%
  • 8.38%
  • 5.32%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.57
  • 8.76
  • 11.98

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.89
  • 11.09
  • 9.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.54
  • 9.43
  • 7.42

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.05
  • 24.93
  • 20.18

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.73
  • 5.63
  • 4.57

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.01
  • 17.02
  • 16.40

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Net Sales
3,638.10
3,577.90
1.68%
3,366.60
2,961.20
13.69%
3,496.30
2,893.70
20.82%
3,732.80
3,237.80
15.29%
Expenses
2,944.90
2,738.00
7.56%
2,741.00
2,273.40
20.57%
2,864.30
2,248.70
27.38%
2,932.40
2,382.70
23.07%
EBITDA
693.20
839.90
-17.47%
625.60
687.80
-9.04%
632.00
645.00
-2.02%
800.40
855.10
-6.40%
EBIDTM
19.05%
23.47%
18.58%
23.23%
18.08%
22.29%
21.44%
26.41%
Other Income
20.10
31.00
-35.16%
26.90
30.40
-11.51%
22.60
101.30
-77.69%
38.40
44.00
-12.73%
Interest
80.50
45.50
76.92%
89.70
35.70
151.26%
89.10
35.00
154.57%
77.30
15.40
401.95%
Depreciation
174.10
153.70
13.27%
172.30
147.50
16.81%
171.60
141.80
21.02%
155.60
144.00
8.06%
PBT
457.10
671.70
-31.95%
122.40
535.00
-77.12%
393.90
569.50
-30.83%
605.90
739.70
-18.09%
Tax
92.70
158.60
-41.55%
39.50
124.70
-68.32%
79.10
120.30
-34.25%
126.70
144.20
-12.14%
PAT
364.40
513.10
-28.98%
82.90
410.30
-79.80%
314.80
449.20
-29.92%
479.20
595.50
-19.53%
PATM
10.02%
14.34%
2.46%
13.86%
9.00%
15.52%
12.84%
18.39%
EPS
3.65
4.99
-26.85%
1.05
4.08
-74.26%
2.96
4.50
-34.22%
4.49
5.77
-22.18%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
14,233.80
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
7,224.00
6,357.70
5,263.30
4,630.60
3,686.80
Net Sales Growth
12.34%
10.13%
27.49%
-0.53%
8.96%
19.76%
13.63%
20.79%
13.66%
25.60%
 
Cost Of Goods Sold
5,046.00
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
2,036.80
1,464.10
1,286.20
1,011.20
Gross Profit
9,187.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
4,811.40
4,320.90
3,799.20
3,344.40
2,675.60
GP Margin
64.55%
68.54%
69.41%
67.31%
71.64%
67.47%
66.60%
67.96%
72.18%
72.22%
72.57%
Total Expenditure
11,482.60
10,197.60
9,125.90
7,475.00
7,097.30
6,897.40
6,031.20
5,234.00
4,181.50
3,614.10
2,878.20
Power & Fuel Cost
-
247.20
226.30
174.50
168.80
145.40
129.70
124.40
93.40
78.90
66.00
% Of Sales
-
1.88%
1.89%
1.86%
1.79%
1.68%
1.80%
1.96%
1.77%
1.70%
1.79%
Employee Cost
-
2,099.40
1,825.20
1,485.20
1,261.60
1,096.50
974.00
818.40
679.90
584.00
401.10
% Of Sales
-
15.95%
15.27%
15.84%
13.38%
12.67%
13.48%
12.87%
12.92%
12.61%
10.88%
Manufacturing Exp.
-
1,334.70
1,211.40
955.30
1,019.60
1,136.90
936.50
897.30
718.90
553.40
429.10
% Of Sales
-
10.14%
10.13%
10.19%
10.82%
13.14%
12.96%
14.11%
13.66%
11.95%
11.64%
General & Admin Exp.
-
589.10
504.60
466.00
432.70
326.80
365.70
342.20
271.90
234.90
218.50
% Of Sales
-
4.47%
4.22%
4.97%
4.59%
3.78%
5.06%
5.38%
5.17%
5.07%
5.93%
Selling & Distn. Exp.
-
1,035.40
1,014.50
826.40
979.60
960.30
902.40
857.50
767.40
710.70
585.30
% Of Sales
-
7.86%
8.49%
8.81%
10.39%
11.10%
12.49%
13.49%
14.58%
15.35%
15.88%
Miscellaneous Exp.
-
750.50
687.00
502.60
561.80
417.40
310.30
157.40
185.90
166.00
585.30
% Of Sales
-
5.70%
5.75%
5.36%
5.96%
4.82%
4.30%
2.48%
3.53%
3.58%
4.53%
EBITDA
2,751.20
2,968.00
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
1,123.70
1,081.80
1,016.50
808.60
EBITDA Margin
19.33%
22.54%
23.66%
20.28%
24.71%
20.27%
16.51%
17.67%
20.55%
21.95%
21.93%
Other Income
108.00
206.20
113.30
147.10
116.60
57.20
58.00
38.40
53.00
22.80
15.90
Interest
336.60
193.50
91.10
63.10
52.80
67.90
90.20
168.70
182.70
69.90
82.10
Depreciation
673.60
598.60
538.80
373.30
292.10
287.30
201.20
184.70
157.90
126.90
133.90
PBT
1,579.30
2,382.10
2,312.00
1,612.20
2,101.20
1,455.90
959.40
808.70
794.20
842.50
608.50
Tax
338.00
530.30
564.40
128.90
177.40
259.40
106.00
118.80
113.00
106.40
74.10
Tax Rate
21.40%
22.26%
24.41%
8.00%
8.45%
17.95%
11.25%
14.69%
14.23%
12.63%
12.27%
PAT
1,241.30
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
653.50
652.60
711.00
506.00
PAT before Minority Interest
1,213.70
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
836.20
689.90
681.20
736.10
529.80
Minority Interest
-27.60
-49.90
-34.60
-29.10
-30.40
-37.60
-32.60
-36.40
-28.60
-25.10
-23.80
PAT Margin
8.72%
13.69%
14.33%
15.51%
20.06%
13.28%
11.12%
10.28%
12.40%
15.35%
13.72%
PAT Growth
-36.93%
5.19%
17.82%
-23.11%
64.64%
42.92%
22.97%
0.14%
-8.21%
40.51%
 
Unadjusted EPS
12.15
18.06
17.35
14.53
19.19
11.24
39.25
31.92
31.87
34.73
24.67

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
2,944.50
2,585.90
2,171.50
1,628.50
Share Capital
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
68.20
Total Reserves
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
2,842.10
2,483.50
2,069.10
1,560.30
Non-Current Liabilities
3,491.10
2,122.20
1,903.30
736.10
1,341.50
1,589.20
1,640.00
1,555.10
956.30
1,204.60
Secured Loans
1,578.00
200.60
319.60
393.80
664.00
851.40
917.20
901.90
670.90
978.20
Unsecured Loans
2,371.70
2,354.50
2,148.80
502.60
486.40
510.80
508.80
420.40
92.00
112.30
Long Term Provisions
184.10
155.90
151.20
120.70
90.40
76.10
66.50
75.60
61.90
0.00
Current Liabilities
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
2,670.40
2,191.60
1,415.90
871.10
Trade Payables
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
910.80
656.80
545.50
570.60
619.60
Other Current Liabilities
2,033.60
1,484.90
1,212.10
860.70
628.20
708.10
509.20
730.90
367.30
56.40
Short Term Borrowings
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
902.40
1,257.10
687.10
259.80
0.00
Short Term Provisions
189.40
152.20
68.90
81.30
382.50
292.70
247.30
228.10
218.20
195.10
Total Liabilities
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60
3,743.40
Net Block
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
3,025.60
2,857.10
1,832.60
1,684.40
Gross Block
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
4,664.00
4,376.20
3,990.90
2,801.70
2,557.80
Accumulated Depreciation
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
1,540.20
1,350.60
1,096.00
929.90
835.00
Non Current Assets
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
4,182.50
3,610.00
2,485.30
1,953.30
Capital Work in Progress
837.20
1,527.20
1,543.30
950.80
797.90
891.50
735.60
483.90
431.00
211.10
Non Current Investment
443.60
470.90
385.70
217.10
33.20
22.20
21.20
21.20
20.70
20.70
Long Term Loans & Adv.
410.40
300.00
384.70
661.20
637.10
511.10
400.10
247.80
201.00
0.00
Other Non Current Assets
159.80
130.30
234.10
174.70
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
3,191.70
2,813.00
2,125.30
1,779.90
Current Investments
229.90
274.80
49.10
199.10
121.20
64.40
93.30
3.00
0.00
0.00
Inventories
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
1,213.60
1,090.50
811.90
750.40
Sundry Debtors
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
955.10
920.90
765.20
466.80
Cash & Bank
649.30
1,314.90
1,543.50
638.70
669.90
548.80
583.80
466.60
295.20
250.70
Other Current Assets
980.10
520.70
80.00
124.10
311.50
323.50
345.90
332.00
253.00
312.00
Short Term Loans & Adv.
584.50
527.70
268.50
234.80
240.80
254.90
279.00
274.60
206.20
308.00
Net Current Assets
1,155.60
2,146.70
716.50
819.40
941.60
623.90
521.30
621.40
709.40
908.80
Total Assets
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60
3,743.40

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
2,882.30
919.30
1,311.70
1,893.50
993.60
902.80
603.40
511.10
682.60
695.40
PBT
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
942.20
808.70
794.20
842.50
603.90
Adjustment
664.30
624.30
333.70
249.80
344.50
269.00
315.90
320.90
208.40
228.10
Changes in Working Capital
637.80
-1,383.90
-411.20
271.70
-377.00
-20.10
-201.60
-421.70
-175.30
-123.60
Cash after chg. in Working capital
3,684.20
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
923.00
693.40
875.60
708.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-675.40
-602.30
-237.60
-646.00
-386.90
-172.80
-272.00
-143.50
-152.50
-77.10
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
-126.50
-30.80
14.90
-80.70
-32.50
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-5,738.70
-973.70
-2,871.90
-863.50
-464.70
-438.00
-682.30
-1,199.50
-466.00
-371.60
Net Fixed Assets
-569.90
-600.20
-557.40
-531.50
-271.50
-239.50
-646.90
-361.70
-266.60
-223.80
Net Investments
-1,106.80
305.60
-1,606.20
-108.40
-651.40
-277.80
-67.70
-513.40
-99.90
-3.50
Others
-4,062.00
-679.10
-708.30
-223.60
458.20
79.30
32.30
-324.40
-99.50
-144.30
Cash from Financing Activity
1,884.60
51.50
2,315.80
-934.80
-351.10
-528.70
285.80
859.80
-172.10
-324.80
Net Cash Inflow / Outflow
-971.80
-2.90
755.60
95.20
177.80
-63.90
206.90
171.40
44.50
-1.00
Opening Cash & Equivalents
1,589.70
1,592.60
837.00
737.90
612.60
676.50
469.60
295.20
250.70
251.70
Closing Cash & Equivalent
879.20
1,589.70
1,592.60
837.00
790.40
612.60
676.50
466.60
295.20
250.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
101.43
85.40
67.97
55.66
41.52
33.58
28.75
25.25
21.21
15.82
ROA
9.34%
11.11%
12.18%
20.14%
13.93%
10.89%
10.00%
12.35%
17.62%
14.94%
ROE
19.36%
22.26%
23.43%
38.62%
30.85%
26.20%
24.95%
28.64%
38.85%
37.71%
ROCE
15.88%
18.26%
16.50%
28.60%
23.21%
17.20%
18.21%
24.01%
30.56%
26.55%
Fixed Asset Turnover
1.05
1.38
1.38
1.76
1.80
1.63
1.55
1.58
1.75
1.54
Receivable days
99.21
83.37
76.72
63.29
56.38
51.71
52.78
57.47
47.97
45.13
Inventory Days
70.33
63.69
59.88
54.52
60.13
63.89
64.82
64.85
60.83
66.19
Payable days
72.33
71.11
74.18
67.53
55.78
50.51
43.54
49.87
64.40
75.83
Cash Conversion Cycle
97.21
75.95
62.42
50.28
60.73
65.09
74.05
72.45
44.40
35.49
Total Debt/Equity
0.76
0.62
0.75
0.43
0.62
0.79
0.99
0.89
0.50
0.67
Interest Cover
13.31
26.38
26.55
40.75
22.29
11.45
5.79
5.35
13.05
8.36

News Update


  • Zydus Cadila gets USFDA’s nod for Mesalamine Suppositories
    13th Feb 2020, 11:47 AM

    This will be manufactured at the group's Topical manufacturing facility at Ahmedabad

    Read More
  • Zydus Cadila gets USFDA’s nod for Fluocinonide Cream
    11th Feb 2020, 15:48 PM

    The drug is used to treat a variety of skin conditions

    Read More
  • Cadila Healthcare receives EIR for Ahmedabad facility
    10th Feb 2020, 16:25 PM

    The topical manufacturing facility had completed the USFDA audit from December 16, 2019 to December 20, 2019 with zero 483 observations

    Read More
  • USFDA inspects manufacturing facility of Cadila Healthcare’s arm
    5th Feb 2020, 09:26 AM

    The site manufactures oncology injectables for the regulated markets

    Read More
  • Zydus Cadila gets DCGI’s nod for Saroglitazar Magnesium for treatment of Type II Diabetes
    3rd Feb 2020, 10:19 AM

    The drug was previously approved in the year 2013 for the treatment of Hypertriglyceridemia and Diabetic Dyslipidemia in India

    Read More
  • Cadila Healthcare enters into licensing agreement with CMS
    20th Jan 2020, 15:14 PM

    The company has entered into a licensing agreement for the treatment of anemia in patients with Chronic Kidney Disease not-on-dialysis

    Read More
  • USFDA completes inspection at Cadila Healthcare’s topical manufacturing facility
    20th Dec 2019, 14:45 PM

    At the end of the inspection, no observation 483 is issued

    Read More
  • Cadila Healthcare launches affordable oral anti-diabetic tablet Vinglyn
    12th Dec 2019, 10:23 AM

    Vinglyn is now one of the most affordable brands of Vildagliptin for diabetic patients in India

    Read More
  • Cadila Healthcare receives EIR for Dabhasa unit
    6th Dec 2019, 12:12 PM

    The EIR report stated that the classification of the facility is ‘No Action Indicated (NAI)’

    Read More
  • Zydus Cadila files NDA of Saroglitazar Mg for treatment of NASH with DCGI
    5th Dec 2019, 10:08 AM

    There are currently no treatments available for the treatment of NASH

    Read More
  • Zydus Cadila gets USFDA’s tentative approval for Lorcaserin Hydrochloride Tablets
    3rd Dec 2019, 11:30 AM

    The drug is used together with diet and exercise to treat obesity

    Read More
  • Cadila Healthcare to merge four subsidiaries to consolidate pharma business
    2nd Dec 2019, 15:01 PM

    The company has received an approval from the board of directors for the amalgamation

    Read More
  • Zydus Cadila gets USFDA’s nod for Isosorbide Dinitrate Tablets, Desonide Cream
    21st Nov 2019, 11:20 AM

    The group now has 278 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Cadila declares second Phase 3 trial of Desidustat
    18th Nov 2019, 12:06 PM

    Desidustat is a novel, oral, HIF-PH inhibitor being developed for treating anemia in CKD patients

    Read More
  • Zydus Cadila gets tentative approval from USFDA for Apremilast Tablets
    16th Nov 2019, 15:40 PM

    It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad

    Read More
  • Cadila Healthcare acquires remaining stake in two subsidiaries
    14th Nov 2019, 14:46 PM

    In view of the same, both ZTL and ZNI will become wholly owned subsidiary companies of the company

    Read More
  • Cadila Healthcare - Quarterly Results
    13th Nov 2019, 16:27 PM

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.